Targeting key regulators such as AMPK, PAD2, and TLR9 offers a promising strategy to disrupt the pathological feedback loops between NET formation and macrophage polarization, with the potential to mitigate autoimmune diseases, inflammatory disorders, and cancer progression while preserving essential immune homeostasis. This evidence concerns the gene TLR9 and autoimmune disease.